Corcept Therapeutics (NASDAQ:CORT) Announces Earnings Results

Corcept Therapeutics (NASDAQ:CORT) announced its quarterly earnings data on Wednesday. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.34, FiscalAI reports. Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The business had revenue of $256.15 million during the quarter, compared to analysts’ expectations of $221.15 million. During the same quarter last year, the business posted $0.29 EPS. The business’s quarterly revenue was up 31.7% compared to the same quarter last year.

Here are the key takeaways from Corcept Therapeutics’ conference call:

• Second-quarter revenue rose 32% to $256.1 million, while net income increased to $43 million. Management raised full-year 2026 revenue guidance to $1.1 billion–$1.2 billion, citing strength in both endocrinology and oncology.
• LIFYORLI generated $47.6 million in its first quarter of availability, with more than 1,300 patients initiating treatment and over 1,000 prescribing physicians. Management highlighted broad payer coverage, NCCN preferred-regimen status, and a goal of exceeding $1 billion in U.S. annual revenue for platinum-resistant ovarian cancer.
• Korlym and the authorized generic continued to benefit from record new prescriptions, prescribers, and active patients, with specialty-pharmacy transition issues largely behind the company. Corcept expects its Cushing’s syndrome business to reach at least $2 billion in annual revenue by the end of the decade.
• The FDA accepted relacorilant’s resubmitted Cushing’s syndrome application and assigned a December 17, 2026 PDUFA date. Management believes approval could accelerate growth, supported by positive Phase III data and the potential for a more favorable safety profile than existing treatments.
• Corcept reported encouraging development plans across oncology, MASH, and ALS, including upcoming data from BELLA, STELLA, TRIDENT, and MONARCH. However, dazucorilant’s ALS program still requires a dose-titration study because gastrointestinal side effects caused most discontinuations in the Phase II trial.

Corcept Therapeutics Stock Up 27.4%

NASDAQ:CORT traded up $25.51 during trading hours on Thursday, reaching $118.46. 2,699,585 shares of the company’s stock were exchanged, compared to its average volume of 1,590,522. Corcept Therapeutics has a 1-year low of $28.66 and a 1-year high of $122.21. The firm has a market capitalization of $12.72 billion, a price-to-earnings ratio of 338.47 and a beta of 0.47. The company has a 50-day moving average of $82.51 and a 200 day moving average of $55.80.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CORT. HC Wainwright lifted their price target on shares of Corcept Therapeutics from $95.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday. Truist Financial raised shares of Corcept Therapeutics to a “strong-buy” rating in a research report on Monday, June 15th. Zacks Research upgraded shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 4th. Piper Sandler boosted their price target on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the company an “overweight” rating in a research report on Friday, May 1st. Finally, Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective for the company. in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $106.33.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. Corcept reported adjusted earnings of $0.36 per share, compared with the consensus estimate of $0.02, while revenue reached $256.15 million versus expectations of $221.15 million. Revenue increased 31.7% year over year, and EPS rose from $0.29 in the comparable quarter. Corcept Therapeutics Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Profitability improved. Operating profit rose 54.8% to $41.3 million, net income increased 21.8% to $42.1 million, and the company generated $33.5 million in operating cash flow. Corcept ended the quarter with $111 million in cash and cash equivalents. Corcept Therapeutics Stock Rises on Q2 2026 Earnings
• Positive Sentiment: Management raised its full-year 2026 revenue outlook. The company now expects revenue of approximately $1.1 billion to $1.2 billion, above the roughly $1.0 billion analyst consensus. The improved outlook was a key catalyst for the stock’s after-hours gain. Corcept Therapeutics Shares Surge After Hours
• Neutral Sentiment: Analyst price targets remain mixed. Recent targets range from $72 to $135, with a median of $91.50, suggesting debate over how much of the improved outlook is already reflected in CORT’s valuation.
• Negative Sentiment: Wolfe Research downgraded Corcept Therapeutics to Underperform, providing a counterpoint to the upbeat earnings news. In addition, reported insider activity over the past six months was heavily weighted toward sales, including transactions by several executives. Wolfe Research Downgrades Corcept Therapeutics

Insiders Place Their Bets

In other news, Director David L. Mahoney sold 20,000 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $84.53, for a total transaction of $1,690,600.00. Following the completion of the sale, the director owned 26,147 shares in the company, valued at approximately $2,210,205.91. This represents a 43.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Atabak Mokari sold 40,000 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $81.15, for a total value of $3,246,000.00. Following the completion of the transaction, the chief financial officer owned 16,130 shares in the company, valued at $1,308,949.50. This trade represents a 71.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 300,000 shares of company stock valued at $22,088,050. 20.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Corcept Therapeutics

Hedge funds have recently modified their holdings of the stock. Pathstone Holdings LLC increased its stake in Corcept Therapeutics by 0.8% in the 3rd quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock valued at $1,497,000 after buying an additional 144 shares during the period. Gould Capital LLC boosted its holdings in shares of Corcept Therapeutics by 50.0% in the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 200 shares in the last quarter. Deutsche Bank AG increased its stake in shares of Corcept Therapeutics by 3.4% during the fourth quarter. Deutsche Bank AG now owns 8,446 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 279 shares during the period. Advisory Services Network LLC acquired a new position in shares of Corcept Therapeutics during the third quarter worth about $25,000. Finally, CIBC Private Wealth Group LLC raised its holdings in Corcept Therapeutics by 128.5% during the third quarter. CIBC Private Wealth Group LLC now owns 770 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 433 shares in the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.